IL228626A0 - Formulations with reduced viscosity - Google Patents
Formulations with reduced viscosityInfo
- Publication number
- IL228626A0 IL228626A0 IL228626A IL22862613A IL228626A0 IL 228626 A0 IL228626 A0 IL 228626A0 IL 228626 A IL228626 A IL 228626A IL 22862613 A IL22862613 A IL 22862613A IL 228626 A0 IL228626 A0 IL 228626A0
- Authority
- IL
- Israel
- Prior art keywords
- formulations
- reduced viscosity
- viscosity
- reduced
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161473123P | 2011-04-07 | 2011-04-07 | |
| PCT/US2012/032464 WO2012141978A2 (en) | 2011-04-07 | 2012-04-06 | Formulations with reduced viscosity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL228626A0 true IL228626A0 (en) | 2013-12-31 |
Family
ID=47009919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL228626A IL228626A0 (en) | 2011-04-07 | 2013-09-29 | Formulations with reduced viscosity |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140044727A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2694708A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014510152A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140066124A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103582724A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012243126A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013025845A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2832560A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201391489A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL228626A0 (cg-RX-API-DMAC7.html) |
| SG (1) | SG193964A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012141978A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3295957T (pt) * | 2010-01-15 | 2019-11-12 | Kirin Amgen Inc | Formulação de anticorpo anti il-17ra e regimes terapêuticos para o tratamento de psoríase |
| EP2694100A4 (en) * | 2011-04-07 | 2014-10-01 | Glaxosmithkline Llc | FORMULATIONS HAVING REDUCED VISCOSITY |
| WO2013190047A1 (en) * | 2012-06-21 | 2013-12-27 | Ucb Pharma S.A. | Pharmaceutical formulation |
| FR2994390B1 (fr) | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| EP3200804A4 (en) | 2014-10-01 | 2018-04-18 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| PH12018500379B1 (en) | 2015-08-24 | 2022-11-23 | Glaxosmithkline Ip No 2 Ltd | Biopharmaceutical compositions |
| CN105733250B (zh) * | 2016-05-04 | 2017-12-26 | 山东省药学科学院 | 一种交联聚谷氨酸悬浮液及其制备方法与应用 |
| EP3569224B1 (en) * | 2017-01-11 | 2022-12-14 | Celltrion Inc. | Stable liquid formula |
| JOP20190255A1 (ar) * | 2017-04-28 | 2019-10-27 | Amgen Inc | صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| JP7382232B2 (ja) | 2017-05-02 | 2023-11-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤 |
| CA3063324A1 (en) | 2017-05-16 | 2018-11-22 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| CN110913887A (zh) * | 2017-06-06 | 2020-03-24 | 葛兰素史克有限责任公司 | 用于儿科患者的生物药物组合物和方法 |
| IL277095B2 (en) * | 2018-03-07 | 2025-10-01 | Pfizer | Preparations containing anti-PD-1 antibody |
| MX2021005394A (es) | 2018-11-07 | 2021-07-06 | Merck Sharp & Dohme Llc | Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1). |
| CA3141857A1 (en) * | 2019-04-23 | 2020-10-29 | Amgen Inc. | The use of low molecular weight polyvinylpyrrolidone (pvp) to reduce viscosity of high concentration protein formulations |
| GB202102258D0 (en) * | 2021-02-17 | 2021-03-31 | Arecor Ltd | Novel composition |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1324776B2 (en) * | 2000-10-12 | 2018-03-21 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| US20050164929A1 (en) * | 2000-11-06 | 2005-07-28 | Lupine Logic, Inc. | Methods of preventing and treating inflammatory bowel disease |
| ATE352316T1 (de) * | 2002-11-01 | 2007-02-15 | Glaxosmithkline Biolog Sa | Immunogene zusammensetzung |
| US20050053666A1 (en) * | 2002-12-31 | 2005-03-10 | Stelios Tzannis | Antibody-containing particles and compositions |
| PL1942939T5 (pl) * | 2005-09-30 | 2021-10-11 | Medimmune Limited | Kompozycja przeciwciała interleukiny-13 |
| EP1962907A2 (en) * | 2005-12-21 | 2008-09-03 | Wyeth a Corporation of the State of Delaware | Protein formulations with reduced viscosity and uses thereof |
| US9084777B2 (en) * | 2005-12-28 | 2015-07-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing formulations |
| UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| US20100189721A1 (en) * | 2007-07-06 | 2010-07-29 | Smithkline Beecham Corporation | Antibody formulations |
| ES2750254T3 (es) * | 2007-09-27 | 2020-03-25 | Amgen Inc | Formulaciones farmacéuticas |
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| EP2515941B1 (en) * | 2009-12-21 | 2019-11-13 | F.Hoffmann-La Roche Ag | Pharmaceutical formulation of bevacizumab |
| CA2794864A1 (en) * | 2010-05-03 | 2011-11-10 | Genentech, Inc. | Compositions and methods useful for reducing the viscosity of protein-containing formulations |
-
2012
- 2012-04-06 SG SG2013072434A patent/SG193964A1/en unknown
- 2012-04-06 US US14/110,252 patent/US20140044727A1/en not_active Abandoned
- 2012-04-06 AU AU2012243126A patent/AU2012243126A1/en not_active Abandoned
- 2012-04-06 BR BR112013025845A patent/BR112013025845A2/pt not_active IP Right Cessation
- 2012-04-06 EP EP12771966.4A patent/EP2694708A4/en not_active Withdrawn
- 2012-04-06 JP JP2014504014A patent/JP2014510152A/ja active Pending
- 2012-04-06 EA EA201391489A patent/EA201391489A1/ru unknown
- 2012-04-06 WO PCT/US2012/032464 patent/WO2012141978A2/en not_active Ceased
- 2012-04-06 KR KR1020137029164A patent/KR20140066124A/ko not_active Withdrawn
- 2012-04-06 CA CA2832560A patent/CA2832560A1/en not_active Abandoned
- 2012-04-06 CN CN201280025770.0A patent/CN103582724A/zh active Pending
-
2013
- 2013-09-29 IL IL228626A patent/IL228626A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2694708A2 (en) | 2014-02-12 |
| WO2012141978A2 (en) | 2012-10-18 |
| CN103582724A (zh) | 2014-02-12 |
| KR20140066124A (ko) | 2014-05-30 |
| EP2694708A4 (en) | 2014-10-01 |
| BR112013025845A2 (pt) | 2018-09-04 |
| EA201391489A1 (ru) | 2014-02-28 |
| WO2012141978A3 (en) | 2012-12-27 |
| AU2012243126A1 (en) | 2013-10-17 |
| JP2014510152A (ja) | 2014-04-24 |
| CA2832560A1 (en) | 2012-10-18 |
| US20140044727A1 (en) | 2014-02-13 |
| SG193964A1 (en) | 2013-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL228626A0 (en) | Formulations with reduced viscosity | |
| IL228591A0 (en) | Formulations with reduced viscosity | |
| GB201111438D0 (en) | Formulation | |
| ZA201309221B (en) | Formulation | |
| GB201120616D0 (en) | Composition | |
| GB201119601D0 (en) | Composition | |
| ZA201402456B (en) | Formulation | |
| GB201117037D0 (en) | Composition | |
| GB201121258D0 (en) | Composition | |
| GB201108912D0 (en) | Composition | |
| GB201103964D0 (en) | Composition | |
| GB201322023D0 (en) | Composition | |
| EP2711011A4 (en) | COMPOSITION CONTAINING PANAXADIOL | |
| GB201204957D0 (en) | Composition | |
| GB201110278D0 (en) | Formulations | |
| GB201115211D0 (en) | Composition | |
| GB201106958D0 (en) | Formulation | |
| GB201216884D0 (en) | Composition | |
| LT2726579T (lt) | Kompozicija | |
| GB201118701D0 (en) | Composition | |
| GB201104284D0 (en) | Formulation | |
| GB201105410D0 (en) | Formulations | |
| GB201102795D0 (en) | Formulations | |
| GB201107626D0 (en) | Formulations | |
| GB201107627D0 (en) | Formulations |